Stay updated on Pembrolizumab and Olaparib in NSCLC Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab and Olaparib in NSCLC Clinical Trial page.

Latest updates to the Pembrolizumab and Olaparib in NSCLC Clinical Trial page
- CheckyesterdayChange DetectedThe web page now includes a notice about heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.SummaryDifference5%
- Check8 days agoChange DetectedThe website has been updated from version v2.14.1 to v2.14.2.SummaryDifference0.3%
- Check15 days agoNo Change Detected
- Check23 days agoChange DetectedThe website has been updated to version 2.14.1 on January 16, 2025, following the removal of version 2.14.0 on November 19, 2024.SummaryDifference1%
- Check30 days agoChange DetectedThe website has updated the 'type of intervention' feature from version 2.13.3 to 2.14.0, indicating a significant change in this functionality.SummaryDifference1.0%
- Check59 days agoChange DetectedThe website has been updated from version 2.13.2 to 2.13.3.SummaryDifference0.3%
- Check66 days agoChange DetectedThe website has been updated from version v2.12.2 to v2.13.2, indicating a new release with potential improvements or features.SummaryDifference0.3%
Stay in the know with updates to Pembrolizumab and Olaparib in NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab and Olaparib in NSCLC Clinical Trial page.